Lung cancer staging: 8th edition

T describes the primary tumour, including its size and relationship with nearby structures. N describes whether regional lymph nodes contain cancer and which node areas are involved. M describes distant metastasis, including spread to another organ or a separate area of the lung. These categories are combined into an overall stage group.

The eighth edition refined how tumour size and patterns of spread are grouped. The label helps clinicians communicate clearly, compare treatment approaches, and describe the extent of disease. It does not by itself predict one person’s future or replace discussion of tumour type, genomic findings, general health, and treatment response.

Your team may use scans, tissue sampling, lymph-node assessment, and selected molecular tests to build the stage. Ask whether your stage is based on information before treatment or on findings after surgery. Treatment can involve surgery, radiotherapy, chemotherapy, or another systemic approach, depending on the TNM pattern and the cancer’s biology. Genomic tumour profiling may add information beyond the anatomical stage.

Tell your team promptly about increasing breathlessness, chest pain, coughing blood, persistent hoarseness, new confusion, severe headache, weakness, or difficulty speaking. A symptom such as hoarse voice can have many causes and does not prove lung cancer. Get emergency help for severe breathing difficulty, sudden neurological changes, or collapse.

What are my T, N, and M categories? Which tests contributed to each category? Is the stage clinical or pathological? Does genomic profiling add treatment information? How could the stage change the order or purpose of my treatments?